LABA/LAMA combination in copd: A meta-analysis on the duration of treatment

European Respiratory Review

Volumn 26, Issue 143, 2017, Pages

  Calzetta, Luigino ^a   Rogliani, Paola ^a,b   Ora, Josuel ^b   Puxeddu, Ermanno ^a   Cazzola, Mario ^a   Matera, Maria Gabriella ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LONG ACTING BETA2 AGONIST PLUS LONG ACTING MUSCARINIC ANTAGONIST; RESPIRATORY TRACT AGENT; UNCLASSIFIED DRUG; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT;

ADULT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION DRUG THERAPY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MONOTHERAPY; MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG COST; DRUG EFFECTS; ECONOMICS; FORCED EXPIRATORY VOLUME; LUNG; NETWORK META-ANALYSIS; PATHOPHYSIOLOGY; PREDICTIVE VALUE; QUESTIONNAIRE; TIME FACTOR; TREATMENT OUTCOME; VITAL CAPACITY;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; BRONCHODILATOR AGENTS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG COSTS; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MUSCARINIC ANTAGONISTS; NETWORK META-ANALYSIS; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 85010289798     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.0043-2016     Document Type: Review

References (66)

1. Cazzola M, Calzetta L, Rogliani P, et al. The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Discov 2016; 11: 733-744.
2. Rogliani P, Calzetta L, Cazzola M, et al. Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis. Expert Opin Drug Saf 2016; 15: 1133-1146.
3. Schlueter M, Gonzalez-Rojas N, Baldwin M, et al. Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis. Ther Adv Respir Dis 2016; 10: 89-104.
4. Oba Y, Sarva ST, Dias S. Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax 2016; 71: 15-25.
5. Calzetta L, Rogliani P, Matera MG, et al. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest 2016; 149: 1181-1196.
6. Calzetta L, Matera MG, Cazzola M. Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy. Eur J Pharmacol 2015; 761: 168-173.
7. Cazzola M, Calzetta L, Ora J, et al. Searching for the synergistic effect between aclidinium and formoterol: from bench to bedside. Respir Med 2015; 109: 1305-1311.
8. Cazzola M, Calzetta L, Segreti A, et al. Translational study searching for synergy between glycopyrronium and indacaterol. COPD 2015; 12: 175-181.
9. Russo MW. How to review a meta-analysis. Gastroenterol Hepatol 2007; 3: 637-642.
10. Berger VW, Alperson SY. A general framework for the evaluation of clinical trial quality. Rev Recent Clin Trials 2009; 4: 79-88.
11. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
12. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med 2009; 3: e123-e130.
13. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD. www.goldcopd.org/Date last accessed: November 30, 2015. Date last updated: 2015.
14. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ ERS position paper. Eur Respir J 2004; 23: 932-946.
15. Shariff SZ, Bejaimal SA, Sontrop JM, et al. Retrieving clinical evidence: a comparison of PubMed and Google Scholar for quick clinical searches. J Med Internet Res 2013; 15: e164.
16. Kew KM, Dias S, Cates CJ. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev 2014 ; 3: CD010844.
17. Horita N, Kaneko T. Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan. Int J Chron Obstruct Pulmon Dis 2015; 10: 813-822.
18. Malerba M, Morjaria JB, Radaeli A. Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD-role of umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis 2014; 9: 687-695.
19. Roskell NS, Anzueto A, Hamilton A, et al. Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol. Int J Chron Obstruct Pulmon Dis 2014; 9: 813-824.
20. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
21. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
22. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001; 54: 1046-1055.
23. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000; 53: 1119-1129.
24. Sterne JAC, Harbord RM. Funnel plots in meta-analysis. Stata J 2004; 4: 127-141.
25. Borenstein M. Introduction to Meta-analysis. Chichester, John Wiley & Sons, 2009.
26. Cooper HM, Hedges LV, Valentine JC. The Handbook of Research Synthesis and Meta-analysis. 2nd Edn. New York, Russell Sage Foundation, 2009.
27. Turner JR, Durham TA. Meta-methodology: conducting and reporting meta-analyses. J Clin Hypertens 2014; 16: 91-93.
28. Cazzola M, Calzetta L, Page C, et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur Respir Rev 2015; 24: 451-461.
29. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
30. Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graph Stat 1998; 7: 434-455.
31. Lu G, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. J Am Stat Assoc 2006; 101: 447-459.
32. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011; 64: 163-171.
33. Cahan S, Gamliel E. First among others? Cohen’s “d” vs. alternative standardized mean group difference measures. Pract Assess Res Eval 2011; 16: 1-6.
34. Thorlund K, Imberger G, Walsh M, et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis-a simulation study. PLoS One 2011; 6: e25491.
35. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence-imprecision. J Clin Epidemiol 2011; 64: 1283-1293.
36. Wallace BC, Dahabreh IJ, Trikalinos TA, et al. Closing the gap between methodologists and end-users: R as a computational back-end. J Stat Softw 2012; 49: 1-15.
37. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw 2010; 36: 1-48.
38. van Valkenhoef G, Lu G, de Brock B, et al. Automating network meta-analysis. Res Synth Method 2012; 3: 285-299.
39. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146: 545-555.
40. Dahl R, Chapman KR, Rudolf M, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med 2013; 107: 1558-1567.
41. Maleki-Yazdi MR, Kaelin T, Richard N, et al. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med 2014; 108: 1752-1760.
42. Tashkin DP, Pearle J, Iezzoni D, et al. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD 2009; 6: 17-25.
43. Vogelmeier C, Kardos P, Harari S, et al. Formoterol mono-and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 2008; 102: 1511-1520.
44. Mahler DA, D’Urzo A, Bateman ED, et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012; 67: 781-788.
45. Novartis Pharmaceuticals. Long-term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease. https://clinicaltrials.gov/ct2/show/NCT01285492Date last accessed: November 21, 2015. Date last updated: December 3, 2013.
46. M ahler DA, Kerwin E, Ayers T, et al. FLIGHT1 and FLIGHT 2: efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015; 192: 1068-1079.
47. Vincken W, Aumann J, Chen H, et al. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int J Chron Obstruct Pulmon Dis 2014; 9: 215-228.
48. Maltais F, Singh S, Donald AC, et al. Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials. Ther Adv Respir Dis 2014; 8: 169-181.
49. ® in patients with COPD: results of two randomized, double-blind, active-controlled studies. Int J Chron Obstruct Pulmon Dis 2014; 9: 1133-1144.
50. Singh D, Ferguson GT, Bolitschek J, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med 2015; 109: 1312-1319.
51. Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med 2013; 107: 1538-1546.
52. Celli B, Crater G, Kilbride S, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest 2014; 145: 981-991.
53. Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med 2014; 2: 472-486.
54. D’Urzo AD, Rennard SI, Kerwin EM, et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide/ formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res 2014; 15: 123.
55. Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med 2014; 14: 178.
56. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013; 42: 1484-1494.
57. Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J 2015; 45: 969-979.
58. Donohue JF, Niewoehner D, Brooks J, et al. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res 2014; 15: 78.
59. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013; 1: 199-209.
60. Bateman E. Lack of clinically relevant differences between combination therapy and monotherapy in COPD. Eur Respir J 2014; 43: 1204-1205.
61. van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26: 214-222.
62. Kempsford R, Norris V, Siederer S. Vilanterol trifenatate, a novel inhaled long-acting β2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther 2013; 26: 256-264.
63. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Research Synth Methods 2012; 3: 80-97.
64. Deeks JJ, Higgins J, Altman DG. Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series. The Cochrane Collaboration, 2008; pp. 243-296.
65. Salmon M, Luttmann MA, Foley JJ, et al. Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther 2013; 345: 260-270.
66. Cazzola M, Page CP, Rogliani P, et al. β2-agonist therapy in lung disease. Am J Respir Crit Care Med 2013; 187: 690-696.